SOURCE: Easton Pharmaceuticals Inc.

Easton Pharmaceuticals Inc.

June 18, 2015 08:00 ET

Easton Pharmaceuticals and BMV Medica Sign MOU Towards Exclusive Distribution for Woman's Patented Diagnostic Test for Amniotic Fluid Detection for Women in Late Pregnancy for the Majority of Latin American Countries

Many Countries in the Region Accept US-FDA Approvals With a Minimum Amount of Extra Documentation, Easton / BMV Could Effectively Begin Selling This New Test in These Countries Pending Agreements With Local Distributors

TORONTO, ON--(Marketwired - Jun 18, 2015) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces it has signed an MOU with BMV Medica SA de CV towards the exclusive distribution for most Latin American countries including Argentina, Chile, Colombia, Peru and Ecuador and all of Central America for a patented Diagnostic Test for the only non-invasive monitoring test for amniotic fluid leaks for women in late-stage pregnancies.

The Amniotic Fluid Leak Detection Test -- a valuable new diagnostic test for which Easton / BMV now have the exclusive rights to Latin America, which will enhance Easton / BMV 's franchise and commitment in women's health products. Since many countries in the region accept US-FDA approvals with a minimum amount of extra documentation, Easton / BMV could begin selling this new test in these countries pending agreements with local distributors.

With the pregnancy and birth rates much higher in Latin America than in Western countries like the European Community, the US and Canada, Easton / BMV believe this amniotic fluid leak test will be a success upon launch. This test competes with much more cumbersome, expensive and hard-to-use products, and can be worn as a panty-liner by women during the latter stage of their pregnancy for both detection and prophylaxis.

From a sales & marketing perspective, the same Obstetrician / Gynecologist who would recommend the use of the vaginal detection test would also have at their disposal the ability to recommend use of this amniotic fluid detection test for their late-stage pregnant patients. BMV / Easton believe this new rapid test will quickly gain broad acceptance by many Doctors and women who are looking for a cost-effective, non-invasive, easy-to-use and accurate diagnostic test to avoid unnecessary trips to the hospital or clinic when they are concerned about the cause of the unexpected wetness in late-term pregnancies.

Negotiations have begun between Easton and BMV pertaining to the finer details of marketing with terms on a closed agreement being similar to what presently exists between the two companies. Negotiations are expected to finalize within 2 to 4 weeks. Easton anticipates other positive announcements and developments as per several ongoing discussions, as well as being able to provide consistent updates on all its recently announced initiatives.

Easton Pharmaceuticals and BMV Medica as previously announced are currently involved in a collaborative partnership to equally share profits in Mexico and Latin America for a full line of cancer drugs beginning with Paclitaxel and Docetaxel, manufactured by St. Catherines, Ontario-based Biolyse Pharma Corporation.

In addition, Easton and BMV will equally share profits from the sales of CommonSense LTD's exclusive women's patented diagnostic test in Mexico, a unique test meant to differentiate between a yeast infection and bacterial vaginosis when a woman has vaginal discharge, a common ailment affecting millions of women annually. This test is currently selling in the United States and Canada but as yet unavailable in Latin America.

In other developments, The Company's retained auditor has notified Easton that it cannot complete and sign off on its audit until receiving PCAOB certification as required and requested by Easton. Certification is expected within the next few weeks.

In other developments, The Company announces it has appointed Mr. Nunzio Valerie to the position of President / Secretary / Director to the Corporation. An official announcement is forthcoming alongside other anticipated announcements of other appointments.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other conditions that are all in various stages of development and approval. Easton has entered into a 50 / 50 revenue sharing agreement towards being the exclusive distributor in Mexico for patented women's diagnostic products. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC; a company holding Medical Marijuana growing rights in California on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies, a company who own rights to a product called the groZONE anti-microbial airflow system and hold an exclusive option to purchase up to 49% in a (MMPR) medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope," "positive," "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

Contact Information